PRESS RELEASE

Possible alternative to antibiotics produced by bacteria
Antibacterial substance from staphylococci discovered with new mechanism of action against natural competitors

Bonn, April 29 - Many bacteria produce substances to gain an advantage over competitors in their highly competitive natural environment. Researchers at the University Hospital Bonn (UKB), the University of Bonn and the German Center for Infection Research (DZIF) have discovered a new so-called lantibiotic, namely epilancin A37. It is produced by staphylococci that colonize the skin and acts specifically against their main competitors there, the corynebacteria. This specificity is presumably mediated by a very special mechanism of action, which the researchers were able to decipher in detail. Their results have now been published in the renowned ISME Journal.

Due to increasing antibiotic resistance in pathogens causing infections, the development of new antibacterial substances is important. Hopes are pinned on a new group of substances produced by gram-positive bacteria, the lantibiotics. These are antimicrobial peptides that often have a very narrow spectrum of activity. "Such compounds are highly interesting from a medical point of view, as they could specifically attack individual groups of organisms without affecting the entire bacterial flora, as is the case with broad-spectrum antibiotics, for example," says corresponding author Dr. Fabian Grein, until recently head of the DZIF research group "Bacterial Interference" at the Institute of Pharmaceutical Microbiology at the UKB and member of the Transdisciplinary Research Area (TRA) "Life & Health" at the University of Bonn.

Essential competitive advantage over corynebacteria

The UKB research team led by Fabian Grein and Tanja Schneider, together with the team led by Ulrich Kubitschek, Professor of Biophysical Chemistry at the University of Bonn, have now discovered a new lantibiotic, namely epilancin A37. It is produced by staphylococci, which are typical colonizers of the skin and mucous membranes. Little is known about these antimicrobial peptides. "We were able to show that epilancins are widespread in staphylococci, which underlines their ecological importance," says first author Jan-Samuel Puls, a doctoral student from the University of Bonn at the Institute of Pharmaceutical Microbiology at the UKB. This is because staphylococci and corynebacteria are important genera of the human microbiota - i.e. the totality of all microorganisms such as bacteria and viruses - in the nose and skin, which are closely linked to health and disease. The need to produce such a compound indicates a pronounced competition between the species. The researchers were able to show that the newly discovered epilancin A37 acts very specifically
against corynebacteria, which are among the main competitors of staphylococci within the skin microbiome.

**New mode of action in the "bacterial war" decoded**

"This specificity is presumably mediated by a very special mechanism of action that we were able to decipher in detail," says Grein. Epilancin A37 penetrates the corynebacterial cell, initially without destroying it. The antimicrobial peptides accumulate in the cell and then dissolve the cell membrane from the inside, thus killing the corynebacterium. Co-author Dr. Thomas Fließwasser from the Institute of Pharmaceutical Microbiology at the UKB, postdoctoral researcher at the University of Bonn and acting head of the DZIF research group "Bacterial Interference" adds: "Our study shows how a specific mechanism of action can be used to specifically combat a single bacterial species. It therefore serves us as a 'proof of concept'".

**Promotion:**
This project was funded by the German Center for Infection Research and the Transregio SFB TRR 261 "Antibiotic CellMAP" of the German Research Foundation.

**Publication:**

**Scientific contact:**
Dr. Thomas Fließwasser
Institute for Pharmaceutical Microbiology
Bonn University Hospital
Phone (+49) 228/73-7923
E-mail: fliesswasser@uni-bonn.de

**Image material:**
**Caption:** (from left to right) Prof. Ulrich Kubitscheck, Jan-Samuel Puls (front), Dominik Brajtenbach and Dr. Fabian Grein discover a new lantibiotic, namely epilancin A37, with a unique mechanism of action.

**Picture credits:** University Hospital Bonn/ Rolf Müller

---

**Corynebacteria under the microscope:**
The green-labeled epilancin A37 accumulates in the blue-stained bacterial cell.

**Picture credits:** University Hospital Bonn (UKB) / Jan-Samuel Puls

---

**Press contact:**
Dr. Inka Väth
Deputy Press Officer at the University Hospital Bonn (UKB)
Communications and Media Office at Bonn University Hospital
Phone: (+49) 228 287-10596
E-mail: inka.vaeth@ukbonn.de

**About Bonn University Hospital:** The UKB treats around 500,000 patients per year, employs around 9,000 staff and has total assets of 1.6 billion euros. In addition to the 3,500 medical and dental students, 550 people are trained in numerous healthcare professions each year. The UKB is ranked first among university hospitals (UK) in NRW in the science ranking and in the Focus clinic list and has the third highest case mix index (case severity) in Germany. In 2022 and 2023, the F.A.Z. Institute recognized the UKB as the most desirable employer and training champion among public hospitals in Germany.